CORC

浏览/检索结果: 共1条,第1-1条 帮助

限定条件                        
已选(0)清除 条数/页:   排序方式:
First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm plus ) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs). 会议论文
JOURNAL OF CLINICAL ONCOLOGY, 2016-05-20
作者:  Hirsh, Vera;  Yang, James Chih-Hsin;  Tan, Eng-Huat;  O'Byrne, Ken;  Zhang, Li
收藏  |  浏览/下载:7/0  |  提交时间:2020/01/04


©版权所有 ©2017 CSpace - Powered by CSpace